Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection

Mycoses

Volumn 56, Issue 3, 2013, Pages 264-272

  Pannanusorn, Srisuda ^a,b   Fernandez, Victor ^b   Römling, Ute ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Biofilm formation; Bloodstream infection; Candida albicans; Non albicans Candida spp.; Yeast

Indexed keywords

SILASTIC;

ARTICLE; BIOFILM; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; FUNGAL METABOLISM; FUNGUS GROWTH; FUNGUS ISOLATION; IMAGE ANALYSIS; MEASUREMENT; NONHUMAN; PICHIA ANOMALA; PREVALENCE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SERUM; YEAST CELL;

BIOFILMS; CANDIDA ALBICANS; CANDIDEMIA; CELL ADHESION; CULTURE MEDIA; HUMANS; HYPHAE; PREVALENCE; SILICONE ELASTOMERS; SWEDEN; VIRULENCE FACTORS;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 84876316799     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12014     Document Type: Article

References (35)

1. Wisplinghoff H, Bischoff T, Tallent M, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
3. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-13.
4. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-35.
5. Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005; 43: 2729-35.
6. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008; 46: 933-8.
7. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
8. Camps IR. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation. Int J Antimicrob Agents 2008; 32: S119-23.
9. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
10. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-50.
11. Odds FC, Hanson MF, Davidson AD et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-75.
12. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappinscott HM. Microbia biofilms. Annu Rev Microbiol 1995; 49: 711-45.
13. Bruzual I, Riggle P, Hadley S, Kumamoto CA. Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole. J Antimicrob Chemother 2007; 59: 441-50.
14. d'Enfert C. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 2006; 7: 465-70.
15. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-92.
16. Junqueira J, Fuchs B, Muhammed M et al. Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol 2011; 11: 247.
17. Hasan F, Xess I, Wang X, Jain N, Fries BC. Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect 2009; 11: 753-61.
18. Kumar CPG, Menon T. Biofilm production by clinical isolates of Candida species. Med Mycol 2006; 44: 99-101.
19. Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 1244-8.
20. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994; 62: 915-21.
21. Pannanusorn S, Elings MA, Römling U, Fernandez V. Pyrosequencing of a hypervariable region in the internal transcribed spacer 2 to identify clinical yeast isolates. Mycoses 2011; 55: 172-80.
22. Brillowska-Dabrowska A, Schön T, Pannanusorn S et al. A nosocomial outbreak of Candida parapsilosis in southern Sweden verified by genotyping. Scand J Infect Dis 2009; 41: 135-42.
23. Chandra J, Mukherjee PK, Leidich SD et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80: 903-8.
24. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003; 41: 506-8.
25. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-88.
26. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-5.
27. Krom BP, Cohen JB, Feser GEM, Cihlar RL. Optimized candidal biofilm microtiter assay. J Microbiol Methods 2007; 68: 421-3.
28. Schloerb PR. Glucose in parenteral nutrition: a Survey of US Medical Centers. JPEN J Parenter Enteral Nutr 2004; 28: 447-52.
29. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. Biofilm formation by and antifungal susceptibility of Candida Isolates from urine. Appl Environ Microbiol 2007; 73: 1697-703.
30. Estivill D, Arias A, Torres-Lana A, Carrillo-Muñoz AJ, Arévalo MP. Biofilm formation by five species of Candida on three clinical materials. J Microbiol Methods 2011; 86: 238-42.
31. Frade JP, Arthington-Skaggs BA. Effect of serum and surface characteristics on Candida albicans biofilm formation. Mycoses 2010; 54: e154-62.
32. Thein ZM, Samaranayake YH, Samaranayake LP. In vitro biofilm formation of Candida albicans and non-albicans Candida species under dynamic and anaerobic conditions. Arch Oral Biol 2007; 52: 761-7.
33. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009; 47: 681-9.
34. Finkel JS, Mitchell AP. Genetic control of Candida albicans biofilm development. Nat Rev Micro 2011; 9: 109-18.
35. Yi S, Sahni N, Daniels KJ et al. Alternative mating type configurations (a/α versus a/a or α/α) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol 2011; 9: e1001117.